Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Historical Definition of Oligometastatic Disease and Relevant Studies
3. PET Radiotracers Used for Prostate Cancer
4. Studies Integrating PET into Diagnosis and Treatment of Oligometastatic Disease
5. Current Status and Future Directions
6. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Epstein, J.I.; Egevad, L.; Amin, M.B.; Delahunt, B.; Srigley, J.R.; Humphrey, P.A.; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am. J. Surg. Pathol. 2016, 40, 244–252. [Google Scholar] [CrossRef] [PubMed]
- National Comprehensive Cancer Network: Prostate Cancer (Version 3.2022). Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed on 22 April 2022).
- Savir-Baruch, B.; Choyke, P.L.; Rowe, S.P.; Schuster, D.M.; Subramaniam, R.M.; Jadvar, H. Role of (18)F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. Am. J. Roentgenol. 2021, 216, 851–859. [Google Scholar] [CrossRef] [PubMed]
- Friedman, N.C. The Will Rodgers Phenomenon and PSMA PET/CT. J. Nucl. Med. 2022, 63, 966. [Google Scholar] [CrossRef]
- Chen, Y.H.; Ho, U.C.; Kuo, L.T. Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update. Cancers 2022, 14, 1350. [Google Scholar] [CrossRef]
- Kroese, T.E.; van Laarhoven, H.W.M.; Nilsson, M.; Lordick, F.; Guckenberger, M.; Ruurda, J.P.; D’Ugo, D.; Haustermans, K.; van Cutsem, E.; van Hillegersberg, R.; et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur. J. Cancer 2022, 166, 254–269. [Google Scholar] [CrossRef]
- Nesbit, E.G.; Donnelly, E.D.; Strauss, J.B. Treatment Strategies for Oligometastatic Breast Cancer. Curr. Treat. Options Oncol. 2021, 22, 94. [Google Scholar] [CrossRef]
- Fizazi, K.; Tran, N.; Fein, L.; Matsubara, N.; Rodriguez-Antolin, A.; Alekseev, B.Y.; Özgüroğlu, M.; Ye, D.; Feyerabend, S.; Protheroe, A.; et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019, 20, 686–700. [Google Scholar] [CrossRef]
- Sweeney, C.J.; Chen, Y.H.; Carducci, M.; Liu, G.; Jarrard, D.F.; Eisenberger, M.; Wong, Y.N.; Hahn, N.; Kohli, M.; Cooney, M.M.; et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N. Engl. J. Med. 2015, 373, 737–746. [Google Scholar] [CrossRef]
- Buelens, S.; Poelaert, F.; Dhondt, B.; Fonteyne, V.; De Visschere, P.; Ost, P.; Verbeke, S.; Villeirs, G.; De Man, K.; Rottey, S.; et al. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urol. Oncol. 2018, 36, 158.e13–158.e20. [Google Scholar] [CrossRef]
- Parker, C.C.; James, N.D.; Brawley, C.D.; Clarke, N.W.; Hoyle, A.P.; Ali, A.; Ritchie, A.W.S.; Attard, G.; Chowdhury, S.; Cross, W.; et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial. Lancet 2018, 392, 2353–2366. [Google Scholar] [CrossRef] [Green Version]
- Boevé, L.M.S.; Hulshof, M.; Vis, A.N.; Zwinderman, A.H.; Twisk, J.W.R.; Witjes, W.P.J.; Delaere, K.P.J.; Moorselaar, R.J.A.V.; Verhagen, P.C.M.S.; van Andel, G.; et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur. Urol. 2019, 75, 410–418. [Google Scholar] [CrossRef] [PubMed]
- Schick, U.; Jorcano, S.; Nouet, P.; Rouzaud, M.; Vees, H.; Zilli, T.; Ratib, O.; Weber, D.C.; Miralbell, R. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013, 52, 1622–1628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gandaglia, G.; Fossati, N.; Stabile, A.; Bandini, M.; Rigatti, P.; Montorsi, F.; Briganti, A. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur. Urol. 2017, 72, 289–292. [Google Scholar] [CrossRef]
- Sridharan, S.; Steigler, A.; Spry, N.A.; Joseph, D.; Lamb, D.S.; Matthews, J.H.; Atkinson, C.; Tai, K.H.; Duchesne, G.; Christie, D.; et al. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother. Oncol. 2016, 121, 98–102. [Google Scholar] [CrossRef]
- Tosoian, J.J.; Gorin, M.A.; Ross, A.E.; Pienta, K.J.; Tran, P.T.; Schaeffer, E.M. Oligometastatic prostate cancer: Definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol. 2017, 14, 15–25. [Google Scholar] [CrossRef]
- Jang, W.S.; Kim, M.S.; Jeong, W.S.; Chang, K.D.; Cho, K.S.; Ham, W.S.; Rha, K.H.; Hong, S.J.; Choi, Y.D. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2018, 121, 225–231. [Google Scholar] [CrossRef]
- Siva, S.; Bressel, M.; Murphy, D.G.; Shaw, M.; Chander, S.; Violet, J.; Tai, K.H.; Udovicich, C.; Lim, A.; Selbie, L.; et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur. Urol. 2018, 74, 455–462. [Google Scholar] [CrossRef]
- Knipper, S.; Beyer, B.; Mandel, P.; Tennstedt, P.; Tilki, D.; Steuber, T.; Graefen, M. Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: A comparison to STAMPEDE arm H. World J. Urol. 2020, 38, 1459–1464. [Google Scholar] [CrossRef]
- Hasan, H.; Deek, M.P.; Phillips, R.; Hobbs, R.F.; Malek, R.; Radwan, N.; Kiess, A.P.; Dipasquale, S.; Huang, J.; Caldwell, T.; et al. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer 2020, 20, 492. [Google Scholar] [CrossRef]
- Sooriakumaran, P.; Wilson, C.; Rombach, I.; Hassanali, N.; Aning, J.; Lamb, A.D.; Cathcart, P.; Eden, C.; Ahmad, I.; Rajan, P.; et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: The Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int. 2022, 130, 43–53. [Google Scholar] [CrossRef] [PubMed]
- Jadvar, H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: Utility and limitations. Eur. J. Nucl. Med. Mol. Imaging 2013, 40 (Suppl. S1), 5–10. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, S.; Nakagomi, K.; Goto, S.; Futatsubashi, M.; Torizuka, T. 11C-choline positron emission tomography in prostate cancer: Primary staging and recurrent site staging. Urol. Int. 2005, 74, 214–220. [Google Scholar] [CrossRef] [PubMed]
- Turkbey, B.; Mena, E.; Shih, J.; Pinto, P.A.; Merino, M.J.; Lindenberg, M.L.; Bernardo, M.; McKinney, Y.L.; Adler, S.; Owenius, R.; et al. Localized prostate cancer detection with 18F FACBC PET/CT: Comparison with MR imaging and histopathologic analysis. Radiology 2014, 270, 849–856. [Google Scholar] [CrossRef] [Green Version]
- Galgano, S.J.; McDonald, A.M.; Rais-Bahrami, S.; Porter, K.K.; Choudhary, G.; Burgan, C.; Bhambhvani, P.; Nix, J.W.; Morgan, D.E.; Li, Y.; et al. Utility of (18)F-Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk Prostate Cancer and Evaluating Response to Initial Androgen Deprivation Therapy: A Prospective Single-Arm Pilot Study. Am. J. Roentgenol. 2021, 217, 3. [Google Scholar] [CrossRef] [PubMed]
- Elschot, M.; Selnaes, K.M.; Sandsmark, E.; Kruger-Stokke, B.; Storkersen, O.; Giskeodegard, G.F.; Tessem, M.B.; Moestue, S.A.; Bertilsson, H.; Bathen, T.F. Combined (18)F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer. J. Nucl. Med. 2018, 59, 762–768. [Google Scholar] [CrossRef] [Green Version]
- Selnaes, K.M.; Kruger-Stokke, B.; Elschot, M.; Willoch, F.; Storkersen, O.; Sandsmark, E.; Moestue, S.A.; Tessem, M.B.; Halvorsen, D.; Kjøbli, E.; et al. (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur. Radiol. 2018, 28, 3151–3159. [Google Scholar] [CrossRef]
- Alemozaffar, M.; Akintayo, A.A.; Abiodun-Ojo, O.A.; Patil, D.; Saeed, F.; Huang, Y.; Osunkoya, A.O.; Goodman, M.M.; Sanda, M.; Schuster, D.M. [(18)F]fluciclovine PET/CT for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. J. Urol. 2020, 204, 734–740. [Google Scholar] [CrossRef]
- Ahuja, K.; Sotoudeh, H.; Galgano, S.J.; Singh, R.; Gupta, N.; Gaddamanugu, S.; Choudhary, G. (18)F-Sodium Fluoride PET: History, Technical Feasibility, Mechanism of Action, Normal Biodistribution, and Diagnostic Performance in Bone Metastasis Detection Compared with other Imaging Modalities. J. Nucl. Med. Technol. 2020, 48, 9–16. [Google Scholar] [CrossRef] [Green Version]
- Eder, M.; Eisenhut, M.; Babich, J.; Haberkorn, U. PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 819–823. [Google Scholar] [CrossRef] [Green Version]
- Arslan, A.; Karaarslan, E.; Güner, A.L.; Sağlıcan, Y.; Tuna, M.B.; Özışık, O.; Kural, A.R. Comparison of MRI, PSMA PET/CT, and Fusion PSMA PET/MRI for Detection of Clinically Significant Prostate Cancer. J. Comput. Assist. Tomogr. 2021, 45, 210–217. [Google Scholar] [CrossRef] [PubMed]
- Calais, J.; Ceci, F.; Eiber, M.; Hope, T.A.; Hofman, M.S.; Rischpler, C.; Bach-Gansmo, T.; Nanni, C.; Savir-Baruch, B.; Elashoff, D.; et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: A prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019, 20, 1286–1294. [Google Scholar] [CrossRef]
- Maurer, T.; Gschwend, J.E.; Rauscher, I.; Souvatzoglou, M.; Haller, B.; Weirich, G.; Wester, H.J.; Heck, M.; Kübler, H.; Beer, A.J.; et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J. Urol. 2016, 195, 1436–1443. [Google Scholar] [CrossRef]
- Schwenck, J.; Rempp, H.; Reischl, G.; Kruck, S.; Stenzl, A.; Nikolaou, K.; Pfannenberg, C.; la Fougère, C. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 92–101. [Google Scholar] [CrossRef] [PubMed]
- Dietlein, M.; Kobe, C.; Kuhnert, G.; Stockter, S.; Fischer, T.; Schomäcker, K.; Schmidt, M.; Dietlein, F.; Zlatopolskiy, B.D.; Krapf, P.; et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol. Imaging Biol. 2015, 17, 575–584. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, H.S.; Leung, J.; Bartholomeusz, D.; Sutherland, P.; Le, H.; Nottage, M.; Iankov, I.; Chang, J.H. Comparative study between (68)Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer. J. Med. Imaging Radiat. Oncol. 2018, 62, 816–822. [Google Scholar] [CrossRef] [PubMed]
- Joice, G.A.; Rowe, S.P.; Pienta, K.J.; Gorin, M.A. Oligometastatic prostate cancer: Shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr. Opin. Urol. 2017, 27, 533–541. [Google Scholar] [CrossRef]
- Sutera, P.; Phillips, R.M.; Deek, M.; Ozyigit, G.; Onal, C.; Tran, P.T. The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging. J. Nucl. Med. 2022, 63, 339–341. [Google Scholar] [CrossRef]
- Miralbell, R.; Buchegger, F. PET/CT imaging and the oligometastatic prostate cancer patient: An opportunity for a curative approach with high-dose radiotherapy? Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1267–1269. [Google Scholar] [CrossRef] [Green Version]
- Garcia, J.R.; Jorcano, S.; Soler, M.; Linero, D.; Moragas, M.; Riera, E.; Miralbell, R.; Lomeña, F. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: Impact on treatment planning. Q. J. Nucl. Med. Mol. Imaging 2015, 59, 342–350. [Google Scholar] [CrossRef]
- Erie, A.J.; Morris, J.M.; Welch, B.T.; Kurup, A.N.; Weisbrod, A.J.; Atwell, T.D.; Schmit, G.D.; Kwon, E.D.; Callstrom, M.R. Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience. J. Vasc. Interv. Radiol. 2017, 28, 987–992. [Google Scholar] [CrossRef] [PubMed]
- Hofman, M.S.; Lawrentschuk, N.; Francis, R.J.; Tang, C.; Vela, I.; Thomas, P.; Rutherford, N.; Martin, J.M.; Frydenberg, M.; Shakher, R.; et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet 2020, 395, 1208–1216. [Google Scholar] [CrossRef]
- Phillips, R.; Shi, W.Y.; Deek, M.; Radwan, N.; Lim, S.J.; Antonarakis, E.S.; Rowe, S.P.; Ross, A.E.; Gorin, M.A.; Deville, C.; et al. Outcomes of Observation vs. Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020, 6, 650–659. [Google Scholar] [CrossRef] [Green Version]
- Guler, O.C.; Engels, B.; Onal, C.; Everaert, H.; Van den Begin, R.; Gevaert, T.; de Ridder, M. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. Clin. Transl. Oncol. 2018, 20, 484–490. [Google Scholar] [CrossRef] [PubMed]
- Onal, C.; Ozyigit, G.; Akgun, Z.; Atalar, B.; Igdem, S.; Oymak, E.; Agaoglu, F.; Selek, U.; Guler, O.C.; Hurmuz, P.; et al. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated with Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study. Clin. Nucl. Med. 2021, 46, 465–470. [Google Scholar] [CrossRef]
- Fossati, N.; Giannarini, G.; Joniau, S.; Sedelaar, M.; Sooriakumaran, P.; Spahn, M.; Rouprêt, M.; EAU Section of Oncological Urology (ESOU) Board. Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. Eur. Urol. Oncol. 2020. [Google Scholar] [CrossRef] [PubMed]
- Fraser, M.; Koontz, B.; Emmenegger, U.; De Meerleer, G.; Khoo, V.; Feng, F.; Corcoran, N.M.; Hovens, C.M.; Tran, P.T.; Ost, P.; et al. What Is Oligometastatic Prostate Cancer? Eur. Urol. Focus 2019, 5, 159–161. [Google Scholar] [CrossRef]
- Aluwini, S.S.; Mehra, N.; Lolkema, M.P.; Oprea-Lager, D.E.; Yakar, D.; Stoevelaar, H.; van der Poel, H.; Dutch Oligometastatic Prostate Cancer Working Group; Busstra, M.; de Jong, I.J.; et al. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. Eur. Urol. Oncol. 2020, 3, 231–238. [Google Scholar] [CrossRef]
- Lecouvet, F.E.; Oprea-Lager, D.E.; Liu, Y.; Ost, P.; Bidaut, L.; Collette, L.; Deroose, C.M.; Goffin, K.; Herrmann, K.; Hoekstra, O.S.; et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: A consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018, 19, e534–e545. [Google Scholar] [CrossRef]
- Connor, M.J.; Winkler, M.; Ahmed, H.U. Survival in Oligometastatic Prostate Cancer-A New Dawn or the Will Rogers Phenomenon? JAMA Oncol. 2020, 6, 185–186. [Google Scholar] [CrossRef]
Radiotracer | Indicated for Initial Staging |
---|---|
18F-FDG | No |
18F-sodium fluoride | Yes |
11C-choline | No |
18F-PSMA/68Ga-PSMA | Yes |
18F-fluciclovine | No |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Galgano, S.J.; McDonald, A.M.; West, J.T.; Rais-Bahrami, S. Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer. Cancers 2022, 14, 3302. https://doi.org/10.3390/cancers14143302
Galgano SJ, McDonald AM, West JT, Rais-Bahrami S. Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer. Cancers. 2022; 14(14):3302. https://doi.org/10.3390/cancers14143302
Chicago/Turabian StyleGalgano, Samuel J., Andrew M. McDonald, Janelle T. West, and Soroush Rais-Bahrami. 2022. "Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer" Cancers 14, no. 14: 3302. https://doi.org/10.3390/cancers14143302